Loading patent…
AssigneeGlobeImmune, Inc.
InventorsRichard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
Estimating the term…
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.
An HCV Core-E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist essentially of an HCV fusion protein comprising a full-length HCV Core protein fused to a full-length HCV E1 protein fused to a full-length HCV E2 protein, wherein the full-length HCV Core protein is linked at its N-terminus to the amino acid sequence represented by SEQ ID NO:9 (MADEAP).
An HCV Core-E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist essentially of a truncated HCV Core protein fused to an HCV E1 protein with deleted transmembrane domain and an HCV E2 protein with deleted transmembrane domain, wherein the truncated HCV Core protein is linked at its N-terminus to the amino acid sequence represented by SEQ ID NO:9 (MADEAP).
An HCV E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist of a an HCV E1 protein fused to an HCV E2 protein, wherein the HCV E1 protein is linked at its N-terminus to the amino acid sequence represented by SEQ ID NO:9 (MADEAP).
Dependencies are inferred from the claim text.